高危非致残性脑血管病——强化治疗的新方向  

High-risk non-disabling ischemic cerebrovascular events(HR-NICE):A new target for aggressive treatment

作　　者：王伊龙[1] 贾茜[1] 王拥军[1] 

机构地区：[1]首都医科大学附属北京天坛医院神经内科,北京100050

出　　处：《科技导报》2017年第4期31-35,共5页Science & Technology Review

基　　金：国家科技支撑计划项目(2011BAI08B02);国家重点研发计划项目(2016YFC0901000)

摘　　要：脑血管病是中国居民死亡率最高的疾病,同时也是引起成人致残的最主要原因之一,其中高危非致残性脑血管病以其临床最常见、病情早期不稳定、复发风险高、及时治疗获益大等特点,近年来逐渐受到广泛关注。本项目组10余年来一直致力于寻找脑血管病的最佳干预人群、创新优化抗栓治疗方案、探寻个体化治疗新方法等,本文结合项目组取得的一系列研究结果,从高危非致残性脑血管病的早期高效识别、有效强化治疗新方案、个体化精准治疗新策略3方面内容对该类型脑血管病进行综述。The cerebrovascular disease is the most common cause for death or adult disability among Chinese population. The High-Risk Non-Disabling Ischemic Cerebrovascular Events（HR-NICE） are very common, and they are unstable in early phases, with good prognosis after effective treatment. In recent years, the HR-NICE has gradually attracted worldwide attentions. Our work has focused on the patients with the highest stroke risk, the most effective antithrombotic therapy, and the most appropriate individualized treatment for more than 10 years. In this paper, we review the early recognition, the diagnosis and the treatment of the HR-NICE.

关 键 词：脑血管事件 治疗 抗栓治疗 

分 类 号：R743.3[医药卫生—神经病学与精神病学]